Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna's financial outlook is bolstered by projected product sales increasing from $1.73 billion in 2025 to $2.15 billion in 2026, reflecting robust revenue growth potential. The recent $1.5 billion debt deal, secured at a competitive interest rate, enhances the company's financial flexibility, positioning it well to navigate uncertainties and capitalize on future opportunities. Additionally, improvements in manufacturing efficiency are anticipated to restore gross margins, which had compressed from 85% during the pandemic to 30% in 2023, back to 50% by 2025, signaling a positive trend in operational profitability.

Bears say

Moderna has reported a significant decline in COVID vaccine sales, with 2023 revenues at $6.7 billion compared to $18 billion in 2022, prompting a reduction in revenue guidance for 2025 due to waning vaccination rates. Additionally, the firm faces competitive pressures in the respiratory vaccine segment, particularly from approved vaccines for RSV, and slower pipeline advancements beyond respiratory applications. Overall, the projected long-term revenue potential for COVID-related products has been substantially lowered, compounding the firm's challenges in achieving robust growth in the near future.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.